Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27645371 | 0.88 | MAPT (0.50) | MAPTKMT2ATDP1MEN1PARP10 | |
| SCHEMBL27645399 | 0.88 | KMT2A (0.50) | MAPTKMT2ATDP1MEN1PARP10 | |
| SCHEMBL2755026 | 0.86 | KMT2A (0.68) | MAPTKMT2ATDP1MEN1PARP10 | |
| SCHEMBL10686135 | 0.85 | ALDH1A1 (0.59) | MAPTKMT2ATDP1MEN1PARP10 | |
| SCHEMBL4425652 | 0.82 | PARP10 (0.65) | MAPTKMT2ATDP1MEN1PARP10 | |
| SCHEMBL6547085 | 0.81 | KMT2A (0.54) | MAPTKMT2ATDP1MEN1PARP10 | |
| SCHEMBL7331658 | 0.81 | F2 (0.51) | MAPTKMT2APKMF2LMNA | |
| SCHEMBL8209293 | 0.79 | MAPT (0.47) | MAPTKMT2ATDP1MEN1PARP10 | |
| SCHEMBL1870544 | 0.79 | PARP10 (0.70) | MAPTKMT2ATDP1MEN1PARP10 | |
| SCHEMBL31888 | 0.79 | PARP10 (0.70) | MAPTKMT2ATDP1MEN1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1867551-B | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists | RAQUALIA PHARMA INC | 2013-09-11 | — | — | CN | disclosed |
| CN-1785993-B | Preparation and use of non-natural isocoumarin derivatives | UNIV NANKAI | 2012-03-14 | — | — | CN | disclosed |
| CN-102186809-A | Insecticidal 4-phenyl-1h-pyrazoles | BAYER CROPSCIENCE AG | 2011-09-14 | — | — | CN | disclosed |
| US-7439011-B2 | Photothermographic material | FUJIFILM CORPORATION (JP) | 2008-10-21 | — | — | US | disclosed |
| US-7439011-B2 | Photothermographic material | FUJIFILM CORPORATION (JP) | 2008-10-21 | — | — | US | disclosed |
| US-7419774-B2 | Photothermographic material and method for processing the same | FUJILFILM CORPORATION (JP) | 2008-09-02 | — | — | US | disclosed |
| US-7419774-B2 | Photothermographic material and method for processing the same | FUJILFILM CORPORATION (JP) | 2008-09-02 | — | — | US | disclosed |
| US-7223528-B2 | Photothermographic material and image forming method | FUJIFILM CORPORATION (JP) | 2007-05-29 | — | — | US | disclosed |
| US-7223528-B2 | Photothermographic material and image forming method | FUJIFILM CORPORATION (JP) | 2007-05-29 | — | — | US | disclosed |
| US-20070003887-A1 | Photothermographic material | RIKIO INOUE | 2007-01-04 | — | — | US | disclosed |
| US-20070003887-A1 | Photothermographic material | RIKIO INOUE | 2007-01-04 | — | — | US | disclosed |
| CN-1867551-A | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists | PFIZER (US) | 2006-11-22 | — | — | CN | disclosed |
| EP-1049662-B1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-6855843-B2 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-15 | — | — | US | disclosed |
| US-20030191118-A1 | Inhibitors of alpha4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-10-09 | — | — | US | disclosed |
| US-6521666-B1 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191118-A1 | Inhibitors of alpha4 mediated cell adhesion | ITGB4, ITGA4, VCAM1 | MAPT 4289/4885KMT2A 3982/4885TDP1 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.